Agent having neurotrophic factor-like activity
AssigneesNagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.
InventorsMunekazu Iinuma, Shoei Furukawa
Life of this patent
Estimating the term…
Abstract
A method for preventing or treating a nervous disorder can include administrating to a person in need of such prevention or treatment a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid. The ester of the decenoic acid can be selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-3-decenoic acid ethyl ester, trans-9-decenoic acid methyl ester, and trans-9-decenoic acid ethyl ester.
Claims10
A method of activating MAP kinases, comprising administering an ester of a decenoic acid to nerve cells, wherein the ester of the decenoic acid is selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-trans-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-3-decenoic acid ethyl ester, trans-9-decenoic acid methyl ester, and trans-9-decenoic acid ethyl ester.
A method for treating depression or anxiety disorder (neurosis), comprising administering a therapeutically effective amount of a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid to a person in need thereof, wherein the ester of the decenoic acid is selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-trans-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, and trans-9-decenoic acid methyl ester.
A method for treating Alzheimer's disease, comprising administering a therapeutically effective amount of a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid to a person in need thereof, wherein the ester of the decenoic acid is selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-trans-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, and trans-9-decenoic acid methyl ester.
Dependencies are inferred from the claim text.